UBS says these 5 consumer-staple stocks are built to weather the uncertain economic storm right now
Consumer staples have dominated the stock market this year, and UBS expects continued strong performance from a specific handful.
Consumer staples have dominated the stock market this year, and UBS expects continued strong performance from a specific handful.
(Bloomberg) -- Senator Elizabeth Warren said that President Donald Trump’s moves to dramatically cut federal regulatory agencies would leave consumers and markets vulnerable to fraud and corruption, magnifying vulnerabilities to a financial system already beset by uncertainty in the face of the White House’s tariffs.Most Read from BloombergTrump Administration Takes Over New York Penn Station RevampDOGE Places Entire Staff of Federal Homelessness Agency on LeaveTrump Signs Executive Orders on Fe
Among the 'Magnificent 7' Big Tech stocks, Apple and Nvidia have found themselves at the forefront of Trump's trade war.
Gold reached all-time highs this week. Wall Street says the rally still has room to run.
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 15.5%. This drop was worse than the S&P 500’s 10% fall.
Business services providers play a critical role for enterprises, assisting them with everything from new hardware integrations to consulting and marketing. Still, investors are uneasy as firms face challenges from AI-driven disruptors and tightening corporate budgets. These doubts have caused the industry to lag recently as services stocks have collectively shed 12.8% over the past six months. This drawdown was worse than the S&P 500’s 10% decline.